CITIUS ONCOLOGY, INC. financial data

Symbol
CTOR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-K - Q3 2025 - 23 Dec 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 41% % 51%
Quick Ratio 35% %
Debt-to-equity 143% %
Return On Equity -64% % 20%
Return On Assets -26% % 20%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84,797,846 shares 19%
Common Stock, Shares, Outstanding 83,513,442 shares 17%
Entity Public Float $5,097,850 USD -100%
Common Stock, Value, Issued $8,351 USD 17%
Weighted Average Number of Shares Outstanding, Basic 73,267,969 shares 7.7%
Weighted Average Number of Shares Outstanding, Diluted 73,267,969 shares 7.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $6,418,334 USD 30%
General and Administrative Expense $8,783,997 USD 7.8%
Operating Income (Loss) $4,944,961 USD -6.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $23,704,409 USD -15%
Income Tax Expense (Benefit) $1,056,960 USD 84%
Net Income (Loss) Attributable to Parent $24,761,369 USD -17%
Earnings Per Share, Basic -0.34 USD/shares -9.7%
Earnings Per Share, Diluted -0.34 USD/shares -9.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $112 USD
Inventory, Net $22,286,693 USD 170%
Assets, Current $27,542,881 USD 151%
Assets $100,942,881 USD 20%
Accounts Payable, Current $13,234,684 USD 257%
Accrued Liabilities, Current $4,093,124 USD
Liabilities, Current $49,491,579 USD 51%
Deferred Income Tax Liabilities, Net $2,784,960 USD 61%
Liabilities $56,076,650 USD 47%
Retained Earnings (Accumulated Deficit) $64,039,956 USD -63%
Stockholders' Equity Attributable to Parent $44,866,231 USD -2.8%
Liabilities and Equity $100,942,881 USD 20%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 400,000,000 shares 300%
Common Stock, Shares, Issued 83,513,442 shares 17%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,924,908 USD 3504282%
Deferred Tax Assets, Valuation Allowance $19,418,000 USD 65%
Deferred Income Tax Expense (Benefit) $264,240 USD 84%
Deferred Tax Assets, Operating Loss Carryforwards $12,720,000 USD 69%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $108,897,836 USD 27%
Share-based Payment Arrangement, Expense $8,116,678 USD 8.2%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%